Inhibition of dextromethorphan metabolism by moclobemide

  title={Inhibition of dextromethorphan metabolism by moclobemide},
  author={Sebastian H{\"a}rtter and Jasper Dingemanse and Dieter Baier and G. Ziegler and Christoph Hiemke},
Abstract This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine. The subjects received seven oral doses of 20 mg dextromethorphan at 4-h intervals over 2 days (1 and 2) and subsequently moclobemide (300 mg b.i.d.) for 9 days. On days 10 and 11, they received seven doses of 20 mg dextromethorphan… Expand
Influence of hydroxychloroquine on the bioavailability of oral metoprolol.
HCQ inhibits metoprolol metabolism most probably by inhibiting its biotransformation by CYP2D6, except in an individual with limited CYP1D6 capacity. Expand
Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.
The results of this study suggest that inhibition of multiple clearance pathways in vivo is clinically relevant, and the risk of DDIs with object drugs may be best evaluated in studies using multi-P450 inhibitors. Expand
Development of neuroleptic agents: pharmacogenetics and current safety issues of regulatory concern
  • R. Shah
  • Medicine
  • Dialogues in clinical neuroscience
  • 2002
The development of safe and effective new drug treatments for schizophrenia poses a challenging task. This class of drugs is known to be associated with a wide range of serious and troublesome safetyExpand
Monitoring of Plasma Concentrations of Psychotropic Drugs in Pharmacovigilance
TDM has the potential to be and become a valuable part of pharmacovigilance when the method is adequately integrated into the clinical treatment process and data can be pooled to emerge large databases for data mining. Expand
Significant Interactions with New Antiretrovirals and Psychotropic Drugs
Given the increasing use of multiple-drug therapy, the potential for drug interactions is extremely high and practitioners need to consider pharmacokinetic, pharmacologic, therapeutic, and adherence factors when managing interactions with complex antiretroviral therapy. Expand
Markers of Individual Drug Metabolism: Towards the Development of a Personalized Antidepressant Prescription.
Recent studies have yielded promising results regarding the potential benefits of determining drug metabolism variability which might encourage additional large-scale prospective systematic studies be set up to assess the relevance of this approach in everyday practice. Expand
Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment.
The number of drugs that are proven or likely major perpetrators of CYP-mediated PK- DDIs is relatively small, and current clinical decision support on PK-DDIs is inconsistent with the published evidence and can be improved using simple criteria. Expand
Serotonin Syndrome Due to an Overdose of Moclobemide and Venlafaxine:Case Report and Review of the Literature
Volume 5 • Issue 6 • 1000193 Clin Exp Pharmacol ISSN: 2161-1459 CPECR, an open access journal Serotonin Syndrome Due to an Overdose of Moclobemide and Venlafaxine: Case Report and Review of theExpand
Death following ingestion of MDMA (ecstasy) and moclobemide.
Four deaths following the ingestion of moclobemide and MDMA ('ecstasy') are described and it seems that each had taken the drug to enhance the effects of MDMA, with fatal consequences. Expand
Drug interactions with the potential to prevent prodrug activation as a common source of irrational prescribing in hospital inpatients
Our objective was to investigate the frequency of potential drug‐drug interactions between the prodrugs losartan, codeine, and tramadol and drugs known to inhibit their activation in hospitalizedExpand


Biotransformation of moclobemide in humans
The structure of the urinary metabolites formed after moclobemide administration in humans was elucidated, and the pattern compared with that in the plasma was found to be qualitatively but not quantitatively similar to that observed in urine. Expand
Dextromethorphan: polymorphic serum pattern of the O-demethylated and didemethylated metabolites in man.
1. The interindividual differences in serum concentrations of dextromethorphan (DM) and its metabolites were studied in 29 healthy subjects given 120 mg orally. They were also phenotyped according toExpand
Dextromethorphan metabolism in rat: interstrain differences and the fate of individually administered oxidative metabolites.
The aims were to determine if there were strain differences also in the Hooded Wistar and Albino Wistar rats with respect to the four dem methylation reactions after dextromethorphan 20 mg/kg intraperitoneally, and to investigate the inhibition of the demethylation reactions by quinine and quinidine. Expand
CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
The data suggest that the N-demethylation of dextromethorphan is dependent on CYP3A and that both CYP2D6 and CYP 3A are involved in the overall metabolism of deXTromethmorphan. Expand
Clinical Pharmacokinetics of the Monoamine Oxidase-A Inhibitor Moclobemide
Moclobemide is an example of a reversible MAO-A inhibitor which has been extensively studied and whose pharmacokinetic, clinical pharmacological and toxicological profiles have been thoroughly defined, and has an excellent tolerability profile both within the therapeutic dose range and in overdose. Expand
Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study *
A combined mephenytoin, sparteine, and caffeine test performed before, during, and after multiple dosing of moclobemide showed changes in the metabolic indexes compatible with a reversible inhibition of oxidation by way of the corresponding CYP enzymes—CYP2C19, CYP2D6, and CYP1A2—during moclOBemide treatment. Expand
Characterization of dextromethorphan N-demethylation by human liver microsomes. Contribution of the cytochrome P450 3A (CYP3A) subfamily.
The kinetics of 3-methoxymorphinan formation were studied in microsomal enzyme systems and a significant correlation was observed between dextromethorphan N-demethylase activity and midazolam 1'- and 4-hydroxylase activity. Expand
Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group.
During moclobemide treatment the sparteine MR rose substantially by a factor of 1-103 (median 4.7), and two EM became phenotypically PM, and in the PM subjects as well as in one EM patient on cimetidine during both tests, no change in spartenine MR occurred. Expand
Primary and secondary oxidative metabolism of dextromethorphan. In vitro studies with female Sprague-Dawley and Dark Agouti rat liver microsomes.
Kinetic parameters and inhibition studies suggest that 3MM and DM O-demethylation pathways in the rat may be mediated by the same cytochrome P450 isozyme. Expand
The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
1. The enzyme kinetics of dextromethorphan O-demethylation in liver microsomes from three extensive metabolisers (EM) with respect to CYP2D6 indicated high (Km1 2.2-9.4 microM) and low (Km2Expand